STING1 and neoplasm: The explanation for this phenomenon relies on the ability of RT to stimulate not only the production of an anti-tumor immune response but also to activate the mechanism of tumor cell resistance to the synergistic immunity to radiotherapy.Using a tumor mouse model, researchers found that RT-mediated activation of STING/type I interferon signaling recruited MDSCs and increased resistance to RT, overcoming tumor immunogenicity.